Tarsus Pharmaceuticals, Inc.

NasdaqGS:TARS 주식 보고서

시가총액: US$1.0b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Tarsus Pharmaceuticals 관리

관리 기준 확인 4/4

Tarsus Pharmaceuticals' CEO는 Bobby Azamian, Nov2016 에 임명되었습니다 의 임기는 7.58 년입니다. 총 연간 보상은 $ 3.13M, 19.8% 로 구성됩니다. 19.8% 급여 및 80.2% 보너스(회사 주식 및 옵션 포함). 는 $ 23.37M 가치에 해당하는 회사 주식의 2.27% 직접 소유합니다. 23.37M. 경영진과 이사회의 평균 재임 기간은 각각 3.1 년과 3.7 년입니다.

주요 정보

Bobby Azamian

최고 경영자

US$3.1m

총 보상

CEO 급여 비율19.8%
CEO 임기7.6yrs
CEO 소유권2.3%
경영진 평균 재임 기간3.1yrs
이사회 평균 재임 기간3.7yrs

최근 관리 업데이트

Recent updates

Following Up On Tarsus Pharmaceuticals

May 28

Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

May 11
Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

Mar 08

Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic

Mar 03
Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 01
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?

Feb 28
Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?

New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Nov 12
New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates

Aug 16
What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates

Tarsus files for FDA approval of TP-03 to treat mite infestation in eyelids

Sep 07

Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues

May 13
Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues

CEO 보상 분석

Bobby Azamian 의 보수는 Tarsus Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$148m

Dec 31 2023US$3mUS$620k

-US$136m

Sep 30 2023n/an/a

-US$108m

Jun 30 2023n/an/a

-US$91m

Mar 31 2023n/an/a

-US$65m

Dec 31 2022US$4mUS$590k

-US$62m

Sep 30 2022n/an/a

-US$63m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$7mUS$550k

-US$14m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$3mUS$437k

-US$27m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$416kUS$300k

-US$5m

보상 대 시장: Bobby 의 총 보상 ($USD 3.13M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 3.43M ).

보상과 수익: Bobby 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Bobby Azamian

7.6yrs

테뉴어

US$3,130,332

보상

Dr. Bobak R. Azamian, also known as Bobby, MD, Ph D, DPhil, is Co-Founder of Tarsus Pharmaceuticals, Inc. and serves as its President since November 2016. He serves as Chief Executive Officer at Tarsus Pha...

리더십 팀

이름위치테뉴어보상소유권
Bobak Azamian
Co-Founder7.6yrsUS$3.13m2.27%
$ 23.4m
Jeffrey S. Farrow
CFO & Chief Strategy Officer1.2yrsUS$3.99m0.0019%
$ 19.1k
Seshadri Neervannan
Chief Operating Officer3.9yrsUS$1.74m0.17%
$ 1.8m
Elizabeth Lin
Chief Medical Advisor & Director3.8yrsUS$180.21k0.079%
$ 815.8k
David Nakasone
Head of Investor Relations2.8yrs데이터 없음데이터 없음
Bryan Wahl
General Counsel & Corporate Secretary3.4yrsUS$2.53m0.11%
$ 1.1m
Adrienne Kemp
Senior Director of Corporate Communications2.2yrs데이터 없음데이터 없음
Matthew Rossen
Vice President of Marketing2.4yrs데이터 없음데이터 없음
Scott Youmans
Vice President of Sales2.3yrs데이터 없음데이터 없음
Dianne Whitfield
Chief Human Resources Officer3.4yrsUS$3.21m0.090%
$ 932.5k
Aziz Mottiwala
Chief Commercial Officer3.8yrs데이터 없음0.14%
$ 1.5m
Cara Miller
Senior Vice President of Corporate Affairsless than a year데이터 없음데이터 없음

3.1yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: TARS 의 관리팀은 경험 ( 3.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Bobak Azamian
Co-Founder7.5yrsUS$3.13m2.27%
$ 23.4m
Elizabeth Lin
Chief Medical Advisor & Director2.4yrsUS$180.21k0.079%
$ 815.8k
William Link
Independent Director7.4yrsUS$183.33k0.65%
$ 6.7m
Wendy Yarno
Lead Independent Director3.6yrsUS$265.83k0.019%
$ 191.0k
Bhaskar Chaudhuri
Independent Director4.5yrsUS$178.58k0.0053%
$ 54.5k
Scott William Morrison
Independent Director1.7yrsUS$186.46k0.0035%
$ 36.4k
Rosemary Crane
Independent Director2.8yrsUS$183.71k0.0053%
$ 54.5k
Andrew Goldberg
Independent Director3.8yrsUS$171.71k0.0079%
$ 81.8k

3.7yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: TARS 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.